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tified through either pharmacy dispensing or provider administration codes. Sev-
eral definitions were applied to identify patients with hemophilia A and B. Health
care utilization and costs for each year were characterized for rFVIIa/FEIBA users.
RESULTS: After excluding 5 states with extensive use of managed care (for which
claimsmay be incomplete), a source population of approximately 63million people
was identified. A total of 130,946 patientsmet the inclusion criteria, of which 10,693
had at least one diagnosis for hemophilia A and 2,032 for hemophilia B. Fewer than
10% were enrolled in managed care in any year. Restricting to males reduced the
sample size to 7292 for hemophilia A (mean age 15.4 years) and 1557 for hemophilia
B (mean age 13.8 years), and these numbers correspond to the expected relative
frequencies of these disorders (4:1). Users of rFVIIa or FEIBAwere approximately 5%
of the cohort and these patients were characterized by extensive use of health care
with on average, a physician visit every 6 weeks and yearly total costs approaching
$1,000,000. CONCLUSIONS: As with any administrative data source, researchers
should be aware of limitations within MAX data, such as the validity of diagnostic
codes and the potential incompleteness of data for certain population subgroups.
Broad demographic coverage, however, large size, and extensive representation of
children make MAX useful, particularly for studying low-prevalence conditions
such as hemophilia.
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PSYCHOMETRIC VALIDATION OF THE PAIN IMPACT QUESTIONNAIRE REVISED
WITH A 1-WEEK RECALL
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QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: The Pain Impact Questionnaire Revised (PIQ-R) is a 6-item patient-
reported measure developed with Item Response Theory and normed against a
general US population sample (GPS). The PIQ-R yields the Pain Impact Score (PIS),
and has been shown to have strong psychometric properties. The traditional stan-
dard PIQ-R uses a 4-week recall; this analysis tested the PIQ-R with a 1-week recall
period. The shorter recall is useful for monitoring interventions with a relatively
rapid impact on pain. METHODS: Identical psychometric tests were run on the
1-week and 4-week PIQ-R using a representative GPS. Internal consistency was
measured with Chronbach’s alpha. Construct validity was tested first by correlat-
ing PIS with a self-reported 0-100 general health rating scale, then by calculating
mean PIS by reported impact of pain condition and other conditions. Discriminant
validity was demonstrated by correlating PIS with the Physical (PCS) and Mental
(MCS) Component Summaries of the SF-12v2 Health Survey. Finally, the unidimen-
sionality of the PIS was explored through factor analysis. RESULTS: Chronbach’s
alpha was .95 for 4-week recall and .96 for 1-week. Correlations between PIS and
general health ratings were strong, at .60 for 4-week recall and .61 for 1-week. The
mean PIS among people with back pain rose monotonically with the reported im-
pact of the condition, for both 1-week and 4-week recall. Conversely, there was no
such rise in PIS by impact of seasonal allergies, which do not generally cause pain.
Among people reporting nomedical conditions,mean PIS in both versionswaswell
below the GPS mean. Both versions of the PIS correlated more strongly with PCS
than with MCS, and exhibited a highly unidimensional structure. CONCLUSIONS:
In all psychometric tests, the 1-week version of the PIQ-R showed nearly identical
results to the 4-week version. Both versions show robust internal consistency,
construct validity, discriminant validity and unidimensionality.
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PREFERENCES FOR IMMUNOGLOBULIN TREATMENT ADMINISTRATION
ATTRIBUTES BY PATIENTS AND PARENTS
Mohamed A1, Kilambi V1, Luo M2, Li-McLeod J3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Baxter BioScience, Deerfield, IL, USA,
3Baxter, Westlake Village, CA, USA
OBJECTIVES: Little is known about the relative importance to patients and their
willingness to accept tradeoffs among immunoglobulin (IG) treatment administra-
tion attributes. The objective of this study was to quantify patient and parent
preferences for administration attributes of IG treatments. METHODS: United
States adult patients and parents of children with a self-reported physician diag-
nosis of a primary immunodeficiency disorder completed a web-enabled, choice-
format conjoint survey that presented a series of 12 choice questions, each includ-
ing a pair of hypothetical IG-treatment profiles. Each profile was defined by mode,
frequency, location, number of needle sticks, and duration. Before answering the
choice questions, respondents were told to assume all treatments worked equally
well. Choice questionswere based on aD-efficient experimental design. Preference
weights for attribute levelswere estimated using random-parameters logit for each
group. All respondents provided online informed consent. RESULTS: A total of 252
patients and 66 parents completed the choice questions appropriately. Both groups
prefered monthly to weekly, home setting, shorter duration and fewer needle
sticks of IG treatment relative to alternative choices (P  0.05). Mode of adminis-
trationwas the least important attribute to both groups; however, parents strongly
preferred self-administration to an appointment with a health care professional (P
 0.05) whereas patients slightly preferred self-administration butwere indifferent
to the two modes. Overall, 98% of parents and 84% of patients preferred therapy
with options of monthly frequency, home setting, shorter duration, and fewer
needle sticks. CONCLUSIONS: IG treatments that provide the option of a monthly
frequency, home setting, shorter duration, and fewer needle sticks may address
the needs of both patients and parents.
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MODERN METHODS OF DELIVERING ADJUVANT RADIOTHERAPY TREATMENT
AND THE RISK OF CARDIAC INJURY IN BREAST CANCER
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OBJECTIVES: To estimate the risk of cardiac injury associated with modern radia-
tion in a population of women with different cardiovascular (CV) risk. METHODS:
The data used for this analysis are from the linked SEER-Medicare database. The
study included women aged 66 years and older with stage 0 - III breast cancer
diagnosed between 2000 and 2005. Women were retrospectively categorized into
low, intermediate, or high risk groups based on the presence of certain clinical
diagnosis. The risk for a hospitalization for a cardiac event was estimated using a
multivariable Cox model. RESULTS: The median follow-up time was 40 months.
Among the 91,612 women with AJCC stage 0 - III breast cancer: 39,555 (43.2%) were
treated with radiation therapy and 52,057 (56.8%) were not. Radiation-treated
women were younger, were likely to have pre-existing CV disease, CV risk factors
and more advanced stage at diagnosis (P  0.001). The following baseline charac-
teristics were significant predictors of an increased risk of hospitalization for a
cardiac event: decreasing year of diagnosis (HRs 1.08– 1.19; 95%CI, 1.02– 1.25), age
at diagnosis (HRs 1.59– 2.50; 95%CI, 2.50– 2.61), AJCC stage I – III (HRs 1.13– 1.29;
95% CI, 1.08– 1.38), the number of comorbid conditions (HRs  1.74– 4.35; 95% CI,
1.68– 4.59), and left-sided tumor (HR  1.03; 95% CI, 1.00– 1.06). Chemotherapy did
confer an elevated risk (HR  1.16; 95% CI, 1.12-1.20) for a hospitalized CV event.
The use of radiotherapy in women categorized as high risk for a future CV
event had an increased risk (HR 1.34; 95% CI, 1.29– 1.39) for a hospitalized CV
event compared to thosewith an intermediate risk or low risk.CONCLUSIONS: The
adverse effects of radiation in high risk patients may require the use of techniques
that minimize the heart from radiation exposure.
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OBJECTIVES:There are limited data suggesting that gastrointestinal (GI) conditions
are common in patients with atrial fibrillation (AF). Many agents utilized by pa-
tients with AF, however, are known to increase the risk of GI events. The study
objective was to describe the risk of GI events among patients with AF.METHODS:
Insurance health care claims between January 2005 and December 2009 from the
Thomson Reuters MarketScan® database were analyzed. Subjects aged 18 years
with 180 days of continuous insurance coverage prior to the index AF diagnosis
were selected. GI events were identified from claims with a primary or secondary
diagnosis code for any GI condition. The subset of GI conditions consistent with
dyspepsia was also reported. The risk of GI events was assessed using cumulative
incidence (new GI events/patients without GI condition at baseline) and incidence
rates (IRs; number of patients with an event/patient-years of observation).
RESULTS:A total of 557,123 AF patients were identified, of whom 143,955 (26%) had
a history of a GI condition at baseline. Themean AF patient age was 68.2 years; 45%
were female. Over the 180-day baseline and mean follow-up of 543 days, 308,823
(55.4%) patients had at least one GI event. Dyspepsia was the most common GI
event seen in 29.6% of patients. The cumulative incidences of any GI event and
dyspepsia were 40% and 19%, respectively. The corresponding IRs were 38.8 and
14.7 events per 100 patient–years, respectively. Additionally, during the baseline
period, 359,398 patients (65%) had at least one medication dispensed that had the
potential to cause GI tolerability issues. CONCLUSIONS: In this large claims data-
base, AF was associated with a 40% risk of developing a GI event, predominantly
dyspepsia. Higher propensity for GI events and agents that selectively cause higher
symptomatic GI rates may relate to poor medication adherence in AF patients.
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EVALUATION OF VTE PROPHYLAXIS, SURGICAL SITE BLEEDING, AND
SURGICAL-SITE INFECTIONS FOLLOWING ORTHOPAEDIC ARTHROPLASTY: A
NESTED CASE–CONTROL MEDICAL CHART REVIEW STUDY
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OBJECTIVES: Post-operative surgical-site infections (SSI) are a leading cause of
prosthetic complications, which include revision surgery. There are insufficient
data to either confirm or refute the hypothesis that post-operative surgical-site
bleeding (SSB) is a mediating pathophysiologic factor linking pharmacologic VTE
prophylaxis to an increased risk of SSI. METHODS: This study addresses this evi-
dence gap by examining the rates and associated risk factors for SSI and yields an
answer on the potential causal relationship between post-discharge thrombopro-
phylaxis, SSB, and subsequent SSI. A cohort of patients with total hip or knee
arthroplasties (from 2005 to 2008) was identified from HealthCore Integrated Re-
searchDatabase (HIRDSM). A random sample of eligible claims recordswas selected
and augmented with the data abstracted from linked hospital medical charts to
conduct a case–control analysis. RESULTS: The study cohort comprised 33,826
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patients (mean age 65 years, mean Deyo-Charlson Comorbidity Index 0.6, mean
hospital length of stay 6.35 days); 214 cases and 214 controls were randomly se-
lected from the cohort for chart data analysis. In the 12 months post-index arthro-
plasty, there were 830 (2.5%) patients who had SSI, 644 (1.9%) who had SSB, and 84
(0.3%) who developed VTE. Of all SSI events, 65% occurred by 90 days following
arthroplasty. Significantly more patients who had received post-discharge throm-
boprophylaxis versus those that did not developed SSI but not SSB (SSI: 28.4% vs
23.2% [P0.0001]; SSB:28.5% vs 23.3% [P0.07]). In the logistic regression analysis,
only the duration of surgery (P0.004), surgical revision (P0.04), and rehospital-
ization (P0.001) emerged as independent predictors of SSI. CONCLUSIONS: Post-
discharge thromboprophylaxis and SSB were not associated with post-operative
SSI, thus dispelling concerns about the increased risk of developing SSI due to
prolonged SSB associated with the use of pharmacologic thromboprophylaxis. Ad-
ditional studies are needed to endorse these findings in similar patient popula-
tions.
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OBJECTIVES: The risk of post-discharge venous thromboembolism (VTE) and
bleeding in total knee and hip arthroplasty (TKA/THA) has not been completely
elucidated because interventions to reduce these adverse outcomes have evolved
rapidly. The objective of this study was to determine the incidence of these events
and associated risk factors, and to evaluate the use of thromboprophylaxis.
METHODS: Administrative medical records (2004–2009) from a large healthcare
plan were linked to an inpatient database of 450 hospitals in the United States.
Adult patients undergoing TKA or THA with no evidence of prior orthopaedic sur-
geries, prior VTE, post-discharge revision surgeries, or death were included. ICD-
9-CM diagnosis and CPT/HCPC procedure codes were used for evaluating symp-
tomatic VTE and bleeding rates 90 days post-surgery. Multivariate analyses were
performed to identify predictors of VTE and bleeding after hospitalization.
RESULTS: Two hundred twenty-six of 9167 patients (2.5%; 3109 THA, 6058 TKA)
with amedian age of 60 years and amean Charlson-Quan comorbidity index score
of 0.5 experienced VTE, and 324 (3.5%) had bleeding. Most of these events occurred
post-discharge (70% and 79%, respectively). Over 50% of VTE occurred within 30
days post-discharge. Consistent predictors of VTE and bleeding after hospitaliza-
tion were inpatient VTE or bleeding, respectively, and all-cause rehospitalization.
Post-discharge thromboprophylaxis was not a significant risk factor for bleeding.
Ninety-eight percent of patients received thromboprophylaxis during hospitaliza-
tion; 26% received it post-discharge. During hospitalization, three-fourths of pa-
tients received enoxaparin and/or warfarin, often in combination withmechanical
prophylaxis devices (57%). Post-discharge, mean antithrombotic drug exposure
was 7.4 days. CONCLUSIONS: Patients who experience VTE or bleeding during
hospitalization and patients who are rehospitalized are at greatest risk of throm-
boembolic and bleeding outcomes, respectively, post-discharge. These data also
suggest that the use of thromboprophylaxis following hospitalization should not
significantly increase the risk of post-discharge bleeding after TKA/THA.
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INTRA-ARTERIAL THROMBOLYSIS VERSUS STANDARD TREATMENT OR
INTRAVENOUS THROMBOLYSIS IN ADULTS WITH ACUTE ISCHEMIC STROKE: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Nam J, He J, O’Reilly D
PATH Research Institute, McMaster University, Hamilton, ON, Canada
OBJECTIVES: Recent evidence has suggested that intra-arterial thrombolysis (IAT)
may provide benefit beyond intravenous thrombolysis (IVT) in ischemic stroke
patients. Previous meta-analyses have only compared IAT to standard treatment
[without thrombolysis]. The objective was to review the benefits and harms of IAT
in ischemic stroke patients. METHODS: EMBASE, MEDLINE, the Cochrane registry
and the stroke trials registry were queried from inception to 2011. Two reviewers
independently screened titles and abstracts for randomized controlled trials of
ischemic stroke comparing IAT to either IVT or standard treatment. Primary out-
comes included good functional outcome, excellent functional outcome, mortality
and symptomatic intracranial hemorrhage. Results were stratified by comparison
treatment. RESULTS: A total of 543 citations were identified. Two trials (n81)
compared IAT to IVT while the remaining four trials (n351) compared IAT to
standard treatment. IAT increased good functional outcome by 47% when com-
pared to standard treatment (RR1.47; 95%CI1.07-2.22; I20) and 74%when com-
pared to IVT (RR1.74; 95%CI1.01-3.01; I20). Excellent functional outcome was
73% higher with IATwhen compared to standard treatment (RR1.73; 95%CI1.17-
2.57; I20) and not significantly different when compared to IVT (RR1.74;
95%CI0.85-3.56), though only one trial reported results for the latter. IAT did not
increase mortality when compared to standard treatment (RR0.82; 95%CI0.56–
1.21; I20) or IVT (RR1.12; 95%CI0.47–2.68; I20). Syptomatic intracranial hem-
orrhage, however, was almost 4 times higher with IATwhen compared to standard
treatment (RR3.90; 95%CI1.41–10.76; I20)while not significantly differentwhen
compared to IVT (RR1.13; 95%CI0.32–3.99; I242%). CONCLUSIONS: Compared
to standard treatment, IAT increases good and excellent functional outcomes;
compared to IVT, IAT increases good functional outcome. As well, IAT does not
increase mortality over IVT or standard treatment. However, IAT increases symp-
tomatic intracranial hemorrhage compared to standard treatment while the risk
remains comparable to IVT. Imprecise pooled estimates for good and excellent
functional outcome prevent any overtly strong recommendation for the use of IAT.
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RISK OF ADVERSE CARDIOVASCULAR OUTCOMES ASSOCIATED WITH
CONCOMITANT USE OF CLOPIDOGREL AND PROTON PUMP INHIBITORS IN
ELDERLY MEDICARE BENEFICIARIES
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OBJECTIVES: Evidence regarding the effect of concomitant use of clopidogrel and
proton pump inhibitors (PPIs) on adverse cardiovascular outcomes remains incon-
clusive. The purpose of the current studywas to examine the effect of concomitant
use of clopidogrel and PPI in a national sample of elderly Medicare beneficiaries
(age 65 years).METHODS: The study used a nested case-control design. A cohort
of Medicare beneficiaries taking clopidogrel for any period between July 1, 2006 and
December 31, 2008 was identified from a 5% national sample of Medicare claims
data using prescription records. Beneficiaries who had a gap of more than 30 days
between clopidogrel fills were excluded. Within the continuous clopidogrel user
cohort, cases [beneficiaries who experienced amajor adverse cardiovascular event
(MACE, composite of acute myocardial infarction, coronary artery bypass graft,
percutaneous coronary intervention, stroke, and mortality)] and controls (benefi-
ciaries who did not experience a MACE) were identified from inpatient and outpa-
tient claims. Concomitant use of clopidogrel and PPI was ascertained using pre-
scription drug records. Each case wasmatched to a control on age and time to start
clopilogrel using a greedy match algorithm. Conditional logistic regression was
conducted on the matched sample to evaluate the association between concomi-
tant use and occurrence of a MACE. RESULTS: A cohort of 43,159 clopidogrel users
was identified. 15,722 of them (36.4%) used clopidogrel and PPI concomitantly at
any time during the study period. 9,332 cases were identified andmatched to equal
number of controls. Beneficiaries using clopidogrel and PPI concomitantly were
more likely to experience a MACE as compared to beneficiaries receiving clopi-
dogrel only (odds ratio: 1.411, 95% Confidence Interval: 1.322 – 1.506).
CONCLUSIONS: Concomitant use of clopidogrel and PPI was associated with an
increased risk of experiencing a cardiovascular adverse event. Caution should be
exercised when co-prescribing the two medications to elderly patients.
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OBJECTIVES: To quantify the impact of atrial fibrillation (AF) and major AF comor-
bidities on risk of cardiovascular (CV) hospitalization (CVH). METHODS: This ret-
rospective cohort study assessed an administrative claims database (Thomson
Reuters’ MarketScan) for newly diagnosed AF patients and demographically
matched non-AF patients to characterize risk of comorbidities and CVH among AF
patients. Patients aged40 yearswith364 days in the databasewere identified by
a qualifying AF diagnosis (2 outpatient diagnoses within 30 days of each other or
1 inpatient diagnosis) from January 1, 2004 to June 29, 2009. RESULTS: A total of
210,524 patients were included (mean age 74.012.5 years, 49% male, 68% Medi-
care). Compared with non-AF patients, AF patients were more likely prescribed
beta blockers (44% vs. 22%), digoxin (15% vs. 2%), and anticoagulants (29% vs. 2%);
had a higher severity of illness (Charlson Comorbidity Index score 4; 16.5% vs.
4.1%); and had higher comorbidity prevalence (odds ratio; 95% confidence interval):
myocardial infarction (13.1; 11.7-14.7), heart failure (HF; 9.2; 8.9-9.6), and pulmo-
nary embolism (8.2; 7.2-9.5). Risk of new CV events and comorbidities at follow-up
was significantly (P0.0001) higher inAFpatients,most notablymajor bleeding, HF,
valvular disease, and stroke. AF patients with baseline comorbidities related to
CHADS2 (score2) or CHA2DS2-VASc (score4) experienced2.5-fold higher rates
of overall CVH. AF patients had 3.4-fold higher CVH risk with30% hospitalized at
1 year vs. 8% of non-AF patients; 24.3% of AF patients experienced recurrent AF
requiring hospitalization (incidence: 176/1000 person-years). CONCLUSIONS: AF
patients have higher burden of baseline CV comorbidities that portend greater risk
of CVH and new CV comorbidities following diagnosis compared to matched
non-AF patients. These data indicate AF recurrence requiring hospitalization and
overall hospitalizations 1 year following diagnosis is common.
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IMPCT OF COMORBIDITIES ON TIME IN THERAPEUTIC RANGE IN PATIENTS
WITH NONVALVULAR ATRIAL FIBRILLATION
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OBJECTIVES: Time in therapeutic range (TTR) may be a quality indicator for anti-
coagulation. Previous studies have demonstrated that heart failure (HF) and other
comorbidities are associated with poorer anticoagulation control; however, this
associationwas not studied in a representative US population. The objectivewas to
determine the association between HF, other comorbidities, patient characteris-
tics, and TTR among patients with nonvalvular atrial fibrillation (NVAF).
METHODS: We analyzed longitudinal patient-level anticoagulation management
records collected between 2006 and 2010 by decision support software, Coag-
Clinic™. Adult patients with NVAF who used warfarin over 12 months with no gap
60 days between visits were identified. The Rosendaal method was used to cal-
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